QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101
QurAlis Corporation announced the first ALS patient dosed in a Phase 1 trial evaluating QRL-101, a Kv7.2/7.3 ion channel opener for hyperexcitability-induced ALS progression. Kv7 is also a validated target for epilepsy. The trial aims to assess safety and tolerability, with topline data expected in H1 2025.
QurAlis to Participate at the Piper Sandler 36th Annual Healthcare Conference
QurAlis Corporation to participate in Piper Sandler 36th Annual Healthcare Conference, Dec 3-5, 2024, in New York, NY. CEO Kasper Roet to present a corporate update on Dec 4, 2024, at 12:30PM ET.
QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF
QRL-201 met or exceeded targeted therapeutic range in ALS treatment, advancing to DRF phase with additional biomarkers and C9orf72-related ALS cohort.
Related Clinical Trials:
QurAlis to Participate at the Stifel 2024 Healthcare Conference
QurAlis Corporation to participate in Stifel 2024 Healthcare Conference on November 18-19, 2024, in New York, NY. CEO Kasper Roet to present a corporate update on November 19, 2024, at 3:35PM ET.
QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical
QurAlis completed dosing in Phase 1 MAD trial of QRL-101, a Kv7.2/7.3 ion channel opener for ALS, with no significant safety concerns reported from the SAD trial. MAD data expected in H1 2025 to support larger ALS studies.
© Copyright 2025. All Rights Reserved by MedPath